KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Retained Earnings: 2019-2025

Historic Retained Earnings for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $2.3 billion.

  • Royalty Pharma's Retained Earnings fell 16.65% to $2.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 billion, marking a year-over-year decrease of 16.65%. This contributed to the annual value of $2.8 billion for FY2024, which is 13.03% up from last year.
  • Royalty Pharma's Retained Earnings amounted to $2.3 billion in Q3 2025, which was up 3.67% from $2.2 billion recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Retained Earnings registered a high of $2.8 billion during Q4 2024, and its lowest value of $1.9 billion during Q1 2021.
  • For the 3-year period, Royalty Pharma's Retained Earnings averaged around $2.4 billion, with its median value being $2.4 billion (2024).
  • Per our database at Business Quant, Royalty Pharma's Retained Earnings surged by 45.86% in 2021 and then dropped by 16.65% in 2025.
  • Quarterly analysis of 5 years shows Royalty Pharma's Retained Earnings stood at $2.3 billion in 2021, then decreased by 12.88% to $2.0 billion in 2022, then climbed by 28.14% to $2.5 billion in 2023, then grew by 13.03% to $2.8 billion in 2024, then declined by 16.65% to $2.3 billion in 2025.
  • Its Retained Earnings was $2.3 billion in Q3 2025, compared to $2.2 billion in Q2 2025 and $2.5 billion in Q1 2025.